Naoto Hirano, PhD, MD

The overarching goal of our research is to devise novel antitumour immunotherapeutic modalities that can cure cancer. We have developed a series of human cell-based artificial antigen-presenting cells (APC) that can generate in vitro large numbers of HLA class I-restricted CD8 T cells, class II-restricted CD4 T cells, polyclonal CD3 T cells and CD1d-restricted iNKT cells. Using these artificial APC, we are conducting basic, translational, and clinical research in human T cell immunology. We are particularly interested in understanding how the interactions between T cells and APC affect priming, expansion, persistence and differentiation of T cells. We also seek to clarify how this leads to the subsequent generation and maintenance of T cell memory. Aspiring researchers and trainees who are eager to conquer cancer by harnessing the power of immunity are welcome to our laboratory.

For a list of Dr. Hirano's publications, please visit PubMed or Scopus.


Associate Director for Research, Tumor Immunotherapy Program, Princess Margaret Cancer Centre
Professor, Department of Immunology, University of Toronto
Clinician Scientist, Ontario Institute for Cancer Research
Investigator, BioCanRx